CINJ-Surgical Gastroinstestina

Medicine & Life Sciences

1. Peritoneal Neoplasms 100%
2. Oncologists 78%
3. Metallochaperones 70%
4. Neoplasms 51%
5. Guidelines 51%
6. Peritoneal Diseases 50%
7. Zinc 47%
8. Liver 37%
9. Palliative Care 34%
10. Colorectal Neoplasms 33%
11. Pharmacists 31%
12. Pathologists 31%
13. Radiologists 31%
14. Yttrium-90 28%
15. Pancreatic Neoplasms 27%
16. Physicians 26%
17. Drug Therapy 24%
18. Doxorubicin 23%
19. Neoplasm Metastasis 23%
20. Survival 23%
21. NSC319726 22%
22. Esophagectomy 21%
23. Adenocarcinoma 21%
24. Pancreaticoduodenectomy 21%
25. Hepatic Artery 20%
26. Hepatocellular Carcinoma 19%
27. Mesothelioma 19%
28. Liver Neoplasms 18%
29. Therapeutics 18%
30. Malignant Mesothelioma 17%
31. Neuroendocrine Tumors 15%
32. Breast Neoplasms 15%
33. Desmoplastic Small Round Cell Tumor 15%
34. Appendiceal Neoplasms 14%
35. Pharmaceutical Preparations 14%
36. Radium 13%
37. Surgical Oncology 12%
38. Thiosemicarbazones 12%
39. Neoadjuvant Therapy 11%
40. Pharmacokinetics 11%
41. Gastrointestinal Stromal Tumors 11%
42. Gastrointestinal Neoplasms 11%
43. Breast 11%
44. Microspheres 10%
45. Copper 10%
46. Patient Care 10%
47. Databases 10%
48. Tea 10%
49. Health Care Outcome Assessment 9%
50. Survival Analysis 9%
51. Parenteral Nutrition 9%
52. Enteral Nutrition 8%
53. Malnutrition 8%
54. Ovarian Neoplasms 8%
55. Radiotherapy 8%
56. Peliosis Hepatis 7%
57. bromobenzene 7%
58. gemcitabine 7%
59. MAP4 7%
60. Cytokine Release Syndrome 7%
61. Colon 7%
62. Nutrition Policy 7%
63. Mucous Membrane 7%
64. Stomach Neoplasms 7%
65. Mortality 7%
66. Ionophores 7%
67. Nutritionists 6%
68. Heterografts 6%
69. Credentialing 6%
70. Stomach 6%
71. Growth 6%
72. Ions 6%
73. Poxviridae 6%
74. Dinoprostone 6%
75. African Continental Ancestry Group 6%
76. Drug Discovery 6%
77. Propensity Score 6%
78. Nutrition Assessment 6%
79. Diaphragmatic Hernia 6%
80. Nivolumab 6%
81. Combined Vaccines 6%
82. Esophageal Neoplasms 6%
83. Vinorelbine 6%
84. Polyphenols 6%
85. Recurrence 6%
86. Infusion Pumps 6%
87. Financial Support 6%
88. Lipoxygenase 6%
89. Unnecessary Procedures 6%
90. Mutant Proteins 6%
91. Esophagogastric Junction 6%
92. Rectal Neoplasms 5%
93. Mutation 5%
94. Capecitabine 5%
95. Acute-Phase Reaction 5%
96. Length of Stay 5%
97. Alleles 5%
98. Gene Editing 5%
99. Albumins 5%
100. Colorectal Surgery 5%
101. Morbidity 5%
102. Carotenoids 5%
103. Wounds and Injuries 5%
104. Metals 5%
105. Facilities and Services Utilization 5%
106. Microwaves 5%
107. Cannabinoids 5%
108. Certification 5%
109. Cholangiocarcinoma 5%
110. Clustered Regularly Interspaced Short Palindromic Repeats 5%
111. Comorbidity 5%
112. Radiation 5%
113. Anal Canal 5%
114. Bevacizumab 5%
115. Proteins 5%
116. Hypercalcemia 5%
117. Peritoneal Cavity 5%
118. Sepsis 5%
119. Phenobarbital 5%
120. Optical Imaging 5%
121. Leukopenia 5%
122. Metformin 5%
123. Odds Ratio 5%